Broadcom Inc (AVGO) Stock Price Today
Aura AI Summary
Key Stats
- $1.98TMarket Cap
- -Volume
- TechnologySector
- $481.5752W High
- $289.6052W Low
- -Typical Hold Time
- $2.02TEnterprise Value
- 0.62%Div Yield
- -Trading Activity
Track Broadcom Inc (AVGO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Broadcom Inc has traded between a low of $289.6 and a high of $481.57, highlighting its annual price range. Buy and sell Broadcom Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Most Recent News
Goldman Sachs downgrades AMD to Sell despite record Q2 revenue and AI growth.
Goldman Sachs downgraded Advanced Micro Devices (AMD) to a Sell rating despite the company reporting record Q2 revenue of $11.54 billion, driven largely by its Data Center segment which accounts for 58% of sales. AMD projects strong Q3 revenue of $13...
Stocks fall sharply amid fraud probe and mixed earnings, with Cellebrite down 29%.
Several stocks dropped significantly today due to various company-specific issues. Cellebrite DI Ltd. plunged 29.18% following a securities fraud investigation, while Securitize Corp. fell 27.48% despite a major NYSE listing milestone. Liftoff Mobile...
Altimmune CEO buys shares, signaling confidence amid strong Q2 results and MASH drug progress.
Altimmune's CEO recently purchased 15,000 shares at $2.95 each, showing strong leadership confidence in the company's future. The biopharmaceutical firm reported a better-than-expected Q2 loss of $0.12 per share and holds $519 million in cash, securi...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.